Rivaroxaban
ApprovedCompleted 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Antiphospholipid Antibody Syndrome
Conditions
Antiphospholipid Antibody Syndrome
Trial Timeline
Sep 1, 2014 → Sep 30, 2017
NCT ID
NCT02116036About Rivaroxaban
Rivaroxaban is a approved stage product being developed by Bayer for Antiphospholipid Antibody Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02116036. Target conditions include Antiphospholipid Antibody Syndrome.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04416048 | Phase 2 | Terminated |
| NCT04096547 | Pre-clinical | UNKNOWN |
| NCT03772457 | Pre-clinical | UNKNOWN |
| NCT02387229 | Phase 3 | Terminated |
| NCT02116036 | Approved | Completed |
| NCT01464450 | Phase 1 | Completed |
| NCT01094886 | Phase 3 | Completed |
Competing Products
4 competing products in Antiphospholipid Antibody Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| RAY121 | Chugai Pharmaceutical | Phase 1 | 33 |
| RAY121 | Chugai Pharmaceutical | Phase 1 | 33 |
| Crovalimab + Placebo + VKA | Roche | Phase 2 | 52 |
| Apixaban + Warfarin | Bristol Myers Squibb | Approved | 84 |